Advertisement

Drugs

, Volume 73, Issue 16, pp 1815–1827 | Cite as

Tobramycin Inhalation Powder: A Review of Its Use in the Treatment of Chronic Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis

Adis Drug Evaluation

Abstract

Inhaled tobramycin, an aminoglycoside antibacterial, has been in widespread use in the form of a nebulized solution against Pseudomonas aeruginosa for many years. More recently, tobramycin inhalation powder (TIP; TOBI® Podhaler) was formulated using PulmoSphere technology for administration as a dry powder via the T-326 Inhaler. This technology enables the administration of an intrapulmonary drug dose that is similar to that achieved with nebulized tobramycin inhalation solution (TIS), but reduces the administration time for TIP to one-third of that for TIS. TIP is approved in several countries, including the EU and US, for use in cystic fibrosis (CF) patients aged ≥6 years with P. aeruginosa infection. In well designed clinical trials in CF patients, the antipseudomonal efficacy of intermittent twice-daily TIP 112 mg was greater than that of placebo in one trial (a second trial was unable to recruit sufficient patient numbers for meaningful analyses), and non-inferior to that of intermittent twice-daily nebulized TIS 300 mg/5 mL with regard to lung function and sputum density of P. aeruginosa. In addition, patients using TIP were more satisfied with their treatment than those using nebulized TIS, largely as a result of improved overall convenience. TIP is generally well tolerated, with a similar safety profile to that of TIS, except for a higher incidence of cough. In conclusion, TIP administered via the T-326 Inhaler is an effective antipseudomonal agent with non-inferior efficacy and generally similar tolerability to that of nebulized TIS in CF patients with chronic P. aeruginosa infection. Compared with nebulized TIS, TIP has a faster delivery and is more portable and convenient.

Keywords

Cystic Fibrosis Tobramycin Cystic Fibrosis Patient Less Square Mean Improve Lung Function 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comments on the article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

References

  1. 1.
    Parkins MD, Elborn JS. Tobramycin Inhalation PowderTM: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis. Expert Rev Respir Med. 2011;5(5):609–22.PubMedCrossRefGoogle Scholar
  2. 2.
    VanDevanter DR, Geller DE. Tobramycin administered by the TOBI Podhaler for persons with cystic fibrosis: a review. Med Devices (Auckl). 2011. doi: 10.2147/MDER.S16360.PubMedGoogle Scholar
  3. 3.
    Farrell PM. The prevalence of cystic fibrosis in the European Union. J Cyst Fibros. 2008;7:450–3.PubMedCrossRefGoogle Scholar
  4. 4.
    Høiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med. 2011;9:32.PubMedCrossRefGoogle Scholar
  5. 5.
    Flume PA, O’Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176(10):957–69.PubMedCrossRefGoogle Scholar
  6. 6.
    Geller DE. Aerosol antibiotics in cystic fibrosis. Respir Care. 2009;54(5):658–69.PubMedCrossRefGoogle Scholar
  7. 7.
    Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168(8):918–51.PubMedCrossRefGoogle Scholar
  8. 8.
    Cheer SM, Waugh J, Noble S. Inhaled tobramycin (TOBI®): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs. 2003;63:2501–20.PubMedCrossRefGoogle Scholar
  9. 9.
    Sawicki GS, Sellers DE, Robinson WM, et al. High treatment burden in adults with cystic fibrosis: challenges to disease self management. J Cyst Fibros. 2009;8(2):91–6.PubMedCrossRefGoogle Scholar
  10. 10.
    European Medicines Agency. TOBI Podhaler 28 mg inhalation powder, hard capsules. Summary of product characteristics. 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002155/WC500110921.pdf. Accessed 17 Oct 2013.
  11. 11.
    Novartis Pharmaceuticals Corporation. TOBI PODHALER (Tobramycin Inhalation Powder). Full prescribing information. 2013. http://www.pharma.us.novartis.com/cs/www.pharma.us.novartis.com/product/pi/pdf/tobipodhaler.pdf. Accessed 17 Oct 2013.
  12. 12.
    Ratjen F, Brockhaus F, Angyalosi G. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review. J Cyst Fibros. 2009;8(6):361–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Ren CL, Konstan MW, Yegin A, et al. Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis. J Cyst Fibros. 2012;11(4):293–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999;340:23–30.PubMedCrossRefGoogle Scholar
  15. 15.
    Heijerman H, Westerman E, Conway S, et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros. 2009;8(5):295–315.PubMedCrossRefGoogle Scholar
  16. 16.
    Geller DE, Weers J, Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphereTM technology. J Aerosol Med Pulm Drug Deliv. 2011;24(4):175–82.PubMedCrossRefGoogle Scholar
  17. 17.
    Newhouse MT, Hirst PH, Duddu SP, et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest. 2003;124(1):360–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Tiddens HA, Geller DE, Challoner P, et al. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older. J Aerosol Med. 2006;19(4):456–65.PubMedCrossRefGoogle Scholar
  19. 19.
    Geller D, Ament B, Heuerding S, et al. Inspiratory flow characteristics of the T-326 dry powder inhaler (DPI) in CF patients [abstract no. 72]. J Cyst Fibros. 2013;12(Suppl):S66.CrossRefGoogle Scholar
  20. 20.
    Haynes A, Ament B, Heng C, et al. In vitro aerosol delivery performance of tobramycin powder for inhalation (TOBI® PODHALER) using inspiratory flow profiles from cystic fibrosis patients [abstract]. 27th Annual North American Cystic Fibrosis Conference; 17–19 Oct 2013; Salt Lake City.Google Scholar
  21. 21.
    Geller DE, Konstan MW, Smith J, et al. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol. 2007;42(4):307–13.PubMedCrossRefGoogle Scholar
  22. 22.
    Nasr S, Nick J, Ezzet N, et al. Reduced administration time for inhaled tobramycin in cystic fibrosis patients: results from the EAGER trial [abstract]. 27th Annual North American Cystic Fibrosis Conference; 17–19 Oct 2013; Salt Lake City.Google Scholar
  23. 23.
    Ruddy J, Emerson J, Moss R, et al. Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin. J Aerosol Med Pulm Drug Deliv. 2013;26(2):69–75.PubMedCrossRefGoogle Scholar
  24. 24.
    Galeva I, Konstan MW, Higgins M, et al. Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial. Curr Med Res Opin. 2013;29(8):947–56.PubMedCrossRefGoogle Scholar
  25. 25.
    Konstan MW, Geller DE, Minic P, et al. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial. Pediatr Pulmonol. 2011;46(3):230–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros. 2011;10(1):54–61.PubMedCrossRefGoogle Scholar
  27. 27.
    Konstan MW, Flume PA, Wan R, et al. Long-term safety and efficacy of tobramycin inhalation powder in cystic fibrosis patients with P. aeruginosa: the EDIT trial and its two open-label extension studies [abstract]. 27th Annual North American Cystic Fibrosis Conference; 17–19 Oct 2013; Salt Lake City.Google Scholar
  28. 28.
    Regnault A, Balp M-M, Kulich K, et al. Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis. J Cyst Fibros. 2012;11(6):494–501.PubMedCrossRefGoogle Scholar
  29. 29.
    Regnault A, Bal MM, Kulich K, et al. Association of treatment satisfaction and compliance of cystic fibrosis (CF) patients using inhaled tobramycin treatment in the EAGER study. 34th European Cystic Fibrosis Conference; 8–11 June 2011, Hamburg.Google Scholar
  30. 30.
    Geller DE, Nasr SZ, Piggott S, et al. Tobramycin inhalation powder in cystic fibrosis patients: response by age group. Respir Care. 2013. doi: 10.4187/respcare.02264.PubMedGoogle Scholar
  31. 31.
    Harrison MJ, McCarthy C, Fleming C, et al. Improved tolerability, adherence and reduced intravenous (IV) antibiotic usage in CF patients receiving inhaled versus nebulised antibiotic prophylaxis. A real world comparison of tobramycin inhaled powder (TIP) and tobramycin inhaled solution (TIS) [abstract no. 74]. J Cyst Fibros. 2013;12(Suppl):S67.CrossRefGoogle Scholar
  32. 32.
    Nash EF, Ahitan B, Brown CJ, et al. Comparison of pharmacy prescription refill frequency in CF adults before and after switching from tobramycin inhalation solution (TIS) to TOBI Podhaler: ‘real world’ evidence of improved adherence [abstract no. 68]. J Cyst Fibros. 2013;12(Suppl):S65.CrossRefGoogle Scholar
  33. 33.
    National Institute for Health and Clinical Excellence (NICE). Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis. 2013 Mar. http://guidance.nice.org.uk/TA276/Guidance/pdf/English. Accessed 19 Aug 2013.
  34. 34.
    Cystic Fibrosis Foundation. Patient registry: annual data report. 2011. http://www.cff.org/LivingWithCF/QualityImprovement/PatientRegistryReport/. Accessed 21 Aug 2013.
  35. 35.
    Doring G, Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros. 2004;3:67–91.PubMedCrossRefGoogle Scholar
  36. 36.
    Littlewood KJ, Higashi K, Jansen JP, et al. A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis. J Cyst Fibros. 2012;11(5):419–26.PubMedCrossRefGoogle Scholar
  37. 37.
    Sawicki GS, Signorovitch JE, Zhang J, et al. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol. 2012;47(1):44–52.PubMedCrossRefGoogle Scholar
  38. 38.
    Murphy TD, Anbar RD, Lester LA, et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol. 2004;38(4):314–20.PubMedCrossRefGoogle Scholar
  39. 39.
    Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest. 2002;121(1):55–63.PubMedCrossRefGoogle Scholar
  40. 40.
    Konstan MW, Wagener JS, Pasta DJ, et al. Clinical use of tobramycin inhalation solution (TOBI®) shows sustained improvement in FEV1 in cystic fibrosis. Pediatr Pulmonol. 2013;. doi: 10.1002/ppul.22874.Google Scholar
  41. 41.
    Mohamed AF, Reed Johnson FR, Balp MM, et al. Convenience and stated adherence for antibiotic treatment of cystic-fibrosis pseudomonas infections [abstract]. 27th Annual North American Cystic Fibrosis Conference; 17–19 Oct 2013; Salt Lake City.Google Scholar
  42. 42.
    Fernandez-Olmos A, Garcia-Castillo M, Maiz L, et al. In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients. Int J Antimicrob Agents. 2012;40(2):173–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Schelstraete P, Haerynck F, Van daele S, et al. Eradication therapy for Pseudomonas aeruginosa colonization episodes in cystic fibrosis patients not chronically colinized by P. aeruginosa. J Cyst Fibros. 2013;12:1–8.Google Scholar
  44. 44.
    Lo D, VanDevanter DR, Flume P, et al. Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent? Resp Med. 2011;105(Suppl 2):S9–17.CrossRefGoogle Scholar
  45. 45.
    Jones AM, Helm JM. Emerging treatments in cystic fibrosis. Drugs. 2009;69(14):1903–10.PubMedCrossRefGoogle Scholar
  46. 46.
    Van Westreenen M, Tiddens HAWM. New antimicrobial strategies in cystic fibrosis. Pediatr Drugs. 2010;12(6):343–52.CrossRefGoogle Scholar
  47. 47.
    Anderson P. Emerging therapies in cystic fibrosis. Ther Adv Respir Dis. 2010;4(3):177–85.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.AdisNorth ShoreNew Zealand

Personalised recommendations